Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00055624" target="_blank" >RIV/00216224:14110/11:00055624 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1515/HMBCI.2011.020" target="_blank" >http://dx.doi.org/10.1515/HMBCI.2011.020</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1515/HMBCI.2011.020" target="_blank" >10.1515/HMBCI.2011.020</a>

Result language
angličtina
Original language name
Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells
Original language description
Cellular senescence leads to an irreversible block of cellular division capacity both in cell culture and in vivo. The induction of an irreversible cell cycle arrest is very useful for treatment of cancer. Histone deacetylases (HDACs) are considered as therapeutic targets to treat cancer patients. HDAC inhibitors repress cancer growth and are used in various clinical trials. Here, we analyzed whether sodium butyrate (NaBu), an inhibitor of class I and II HDACs, induces cellular senescence in neuroblastoma and prostate cancer (PCa) including an androgen-dependent as well as an androgenindependent human PCa cell line. We found that the HDAC inhibitors NaBu and valproic acid (VPA) induce cellular senescence in tumor cells. Interestingly, also an inhibitorof SIRT1, a class HDAC III, induces cellular senescence.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)